Inflammatory arthritis and autoimmune diseases occur when the immune system becomes overactive and attacks healthy tissues. Modern rheumatology treatment focuses not only on relieving symptoms but on controlling the underlying inflammation to prevent long-term damage. Two important groups of medicines used for this purpose are DMARDs and biologic therapies.
What Are DMARDs?
DMARDs (Disease-Modifying Anti-Rheumatic Drugs) reduce harmful immune activity driving inflammation. They are used in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus, Sjögren disease, connective tissue disease and forms of vasculitis. Unlike painkillers, DMARDs help slow or prevent joint damage. Common DMARDs include methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, azathioprine and mycophenolate.
What Are Biologic Therapies?
Biologic medicines are more targeted treatments used when disease remains active despite standard DMARDs, inflammation is moderate to severe, or there is high risk of joint or spinal damage. Biologics block specific parts of the immune system that drive inflammation. Examples include anti-TNF therapies (adalimumab, etanercept, infliximab, golimumab), IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-6 inhibitors (tocilizumab, sarilumab), B-cell targeted therapy (rituximab) and abatacept. Most are given as injections or intravenous infusions.
What Are JAK Inhibitors?
JAK inhibitors are a newer group of targeted tablet treatments that reduce inflammation by blocking specific immune signalling pathways inside cells. Examples include tofacitinib, baricitinib, upadacitinib and filgotinib. They are used in selected patients with rheumatoid arthritis and certain forms of spondyloarthritis. Although taken as tablets, they require similar safety monitoring to biologic therapies. Doctors assess cardiovascular and infection risk carefully before prescribing.
Why Early Treatment Matters
Uncontrolled inflammation can lead to permanent joint damage, spinal stiffness, reduced mobility and organ complications in some autoimmune diseases. Early and appropriate therapy significantly improves long-term outcomes. There is a recognised window of opportunity in early inflammatory disease where treatment has the greatest impact.
Monitoring and Safety
Because these medicines regulate the immune system, regular monitoring is essential. Before starting treatment, screening includes blood tests, chest X-ray, liver and kidney function tests, tuberculosis screening, and hepatitis and HIV screening. During treatment, periodic blood tests ensure safety and effectiveness. With structured specialist supervision, these therapies are widely used and generally safe. Vaccination advice is discussed individually.
The Role of the Specialist Rheumatologist
DMARDs and biologics should be prescribed and monitored under specialist supervision to confirm diagnosis, screen safely, monitor disease activity, adjust medications as needed, and review side effects early. Self-prescribing or stopping without advice can significantly worsen outcomes.
Frequently Asked Questions
Are DMARDs and biologics the same?
No. DMARDs are traditional immune-modifying medicines. Biologics are more targeted therapies used when additional control is needed.
Will I need these medicines lifelong?
Not always. Treatment duration depends on the condition, response and disease activity. Some patients achieve sustained remission.
Can these medicines prevent joint damage?
Yes. When started early and monitored properly, they significantly reduce the risk of long-term damage.
Why is TB screening important before starting biologics?
Some infections, such as dormant (latent) TB, can reactivate when the immune system is suppressed. Screening helps ensure treatment is safe.
What are the risks of JAK inhibitors?
JAK inhibitors are effective but require careful patient selection. In some higher-risk patients, they have been associated with an increased risk of blood clots. Individual risk factors are assessed before starting therapy.
